共 26 条
[1]
Moslehi JJ(2016)Cardiovascular toxic effects of targeted Cancer therapies New England J Med 375 1457-1467
[2]
Hamid A(2022)Cardiovascular safety reporting in contemporary breast cancer clinical trials J Am Heart Assoc 11 e025206-2596
[3]
Anker MS(2019)Representation of patients with Cardiovascular disease in pivotal cancer clinical trials Circulation 139 2594-4361
[4]
Ruckdeschel JC(2022)2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur Heart J 43 4229-37
[5]
Khan MS(2022)The role of cardioprotection in cancer therapy cardiotoxicity: JACC: cardiooncology State-of-the-art review JACC CardioOncol 4 19-undefined
[6]
Tharwani A(2023)A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia Front Med 10 10-undefined
[7]
Oshunbade AA(undefined)undefined undefined undefined undefined-undefined
[8]
Bonsu J(undefined)undefined undefined undefined undefined-undefined
[9]
Charles L(undefined)undefined undefined undefined undefined-undefined
[10]
Guha A(undefined)undefined undefined undefined undefined-undefined